Advair Diskus: Comprehensive Control for Asthma and COPD
| Product dosage: 250mcg | |||
|---|---|---|---|
| Package (num) | Per accuhaler | Price | Buy |
| 1 | $84.38 | $84.38 (0%) | 🛒 Add to cart |
| 2 | $69.81 | $168.75 $139.62 (17%) | 🛒 Add to cart |
| 3 | $64.62 | $253.13 $193.87 (23%) | 🛒 Add to cart |
| 4 | $62.28 | $337.51 $249.11 (26%) | 🛒 Add to cart |
| 5 | $60.67
Best per accuhaler | $421.89 $303.36 (28%) | 🛒 Add to cart |
Advair Diskus is a combination inhaled corticosteroid and long-acting beta2-adrenergic agonist (ICS/LABA) medication indicated for the maintenance treatment of asthma in patients aged 4 years and older and for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is designed to reduce inflammation and relax airway muscles, offering a dual mechanism for superior respiratory management. This prescription medication is not a rescue inhaler and should not be used for treating acute bronchospasm.
Features
- Dual-Action Formula: Contains fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting bronchodilator).
- Dry Powder Inhaler (DPI) Delivery: The Diskus device is breath-activated, requiring no hand-breath coordination.
- Multiple Strengths: Available in fluticasone/salmeterol dosages of 100/50 mcg, 250/50 mcg, and 500/50 mcg per inhalation.
- Pre-Dosed Blisters: Each blister contains a single precise dose of medication.
- Dose Counter: Integrated counter displays remaining doses for adherence tracking.
Benefits
- Provides 24-hour control of asthma and COPD symptoms with twice-daily dosing.
- Reduces frequency and severity of asthma exacerbations.
- Improves lung function (FEV1) and peak expiratory flow.
- Decreases reliance on short-acting rescue inhalers.
- Enhances overall quality of life through better disease management.
- Helps prevent exercise-induced bronchospasm when used regularly.
Common use
Advair Diskus is prescribed for the long-term maintenance treatment of asthma in patients whose disease is not adequately controlled on inhaled corticosteroids or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. It is also indicated for reducing exacerbations in patients with COPD associated with chronic bronchitis and/or emphysema who have a history of exacerbations. It is critical to understand that this medication is for maintenance use only and is not indicated for the relief of acute symptoms.
Dosage and direction
The dosage of Advair Diskus must be individualized based on disease severity and prior therapy. For asthma maintenance in patients aged 4 years and older, the recommended starting dosage is based upon the asthma severity and the patient’s current asthma therapy. The usual recommended dosage is one inhalation of Advair Diskus twice daily (approximately 12 hours apart). For COPD, the recommended dosage is one inhalation of Advair Diskus 250/50 twice daily. Patients must be instructed on proper inhalation technique: open the device, slide the lever until it clicks, exhale fully away from the mouthpiece, place lips firmly around the mouthpiece, and inhale deeply and steadily. The mouth should be rinsed with water without swallowing after each dose to reduce the risk of oropharyngeal candidiasis.
Precautions
Patients using Advair Diskus should be monitored for increased use of short-acting beta2-agonists, as this may indicate deteriorating asthma control. Systemic and local corticosteroid effects, such as adrenal insufficiency, may occur, particularly at higher doses. There is an increased risk of pneumonia in patients with COPD; patients should be monitored for signs and symptoms of pneumonia. Paradoxical bronchospasm may occur immediately following inhalation; if this occurs, treatment should be discontinued immediately. Patients may experience cardiovascular effects, such as increases in pulse rate or blood pressure; use with caution in patients with cardiovascular disorders. Reduced bone mineral density has been observed with long-term administration of inhaled corticosteroids. Growth velocity should be monitored in pediatric patients. Ophthalmic effects (e.g., cataracts, glaucoma) may occur with long-term use.
Contraindications
Advair Diskus is contraindicated in patients with known hypersensitivity to fluticasone propionate, salmeterol, or any ingredient in the formulation. It is contraindicated for the primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required. Due to the presence of salmeterol, a long-acting beta2-adrenergic agonist, Advair Diskus is contraindicated in patients with asthma without the use of a long-term asthma control medication. It should not be used to treat acute symptoms.
Possible side effect
Common side effects (≥1%) include upper respiratory tract infection, pharyngitis, hoarseness/dysphonia, throat irritation, headache, oral candidiasis, bronchitis, cough, nausea and vomiting, and gastrointestinal discomfort. More serious side effects may include pneumonia (in COPD patients), cardiovascular effects (tachycardia, palpitations, chest pain), paradoxical bronchospasm, immunosuppression and increased risk of infections, hypercorticism and adrenal suppression, reduction in bone mineral density, slowed growth in children, and ophthalmic effects (cataracts, glaucoma). Allergic reactions, including anaphylaxis, rash, urticaria, and angioedema, may occur.
Drug interaction
Concomitant use with strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) is not recommended, as they may increase systemic exposure to fluticasone propionate and increase the risk of systemic corticosteroid effects. Beta-blockers may block the therapeutic effects of beta-agonists and produce severe bronchospasm in patients with asthma; therefore, use with caution. Diuretics or non-potassium sparing diuretics may potentiate the possible hypokalemic effect of beta2-agonists. Use with other products containing long-acting beta2-agonists is contraindicated due to the increased risk of overdose. Monoamine oxidase inhibitors and tricyclic antidepressants may potentiate the cardiovascular effects of beta-agonists.
Missed dose
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take two doses at one time to make up for a missed dose.
Overdose
Overdosage may result in exaggeration of the known pharmacologic effects of the components: fluticasone propionate and salmeterol. Expected effects with salmeterol overdose include tachycardia, arrhythmias, tremor, headache, and hypokalemia. Fluticasone propionate overdose may lead to systemic corticosteroid effects such as hypercorticism. Treatment involves discontinuation of the drug together with institution of appropriate symptomatic and supportive therapy. Cardiac monitoring is recommended in cases of overdose. The Diskus device delivers a fixed dose per inhalation; overdose is unlikely from the inhalation route but could occur with accidental oral ingestion of the powder.
Storage
Store Advair Diskus at room temperature between 68°F and 77°F (20°C and 25°C) in a dry place away from direct heat or sunlight. Keep in the unopened foil pouch until ready for use. After opening the pouch, the device must be used within one month. The device should be stored with the mouthpiece down. Keep out of reach of children. Do not puncture or incinerate the canister. Do not use the device if it has been damaged or if the mouthpiece is detached. Discard the device when the counter reads “0” or 1 month after removal from the foil pouch, whichever comes first.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Individual patient needs and responses to medication may vary. Advair Diskus is available by prescription only and must be used under the supervision of a healthcare professional.
Reviews
Clinical studies have demonstrated that Advair Diskus significantly improves lung function and reduces exacerbation rates compared to monotherapy with inhaled corticosteroids in moderate to severe asthma. In COPD, it has been shown to reduce the rate of moderate and severe exacerbations. Patient-reported outcomes consistently show improvements in quality of life measures. However, real-world effectiveness depends heavily on proper inhaler technique and adherence to the prescribed regimen. Common patient-reported benefits include reduced nighttime symptoms, improved exercise tolerance, and decreased rescue inhaler use. Criticisms occasionally note the cost of the medication and the potential for oral thrush if rinsing is not performed consistently.